Traws Pharma (TRAW) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to -$632.5 million.
- Traws Pharma's Retained Earnings fell 214.93% to -$632.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$632.5 million, marking a year-over-year decrease of 214.93%. This contributed to the annual value of -$649.2 million for FY2024, which is 3450.32% down from last year.
- Traws Pharma's Retained Earnings amounted to -$632.5 million in Q3 2025, which was down 214.93% from -$628.6 million recorded in Q2 2025.
- In the past 5 years, Traws Pharma's Retained Earnings registered a high of -$433.3 million during Q1 2021, and its lowest value of -$649.2 million during Q4 2024.
- Moreover, its 5-year median value for Retained Earnings was -$473.7 million (2023), whereas its average is -$512.6 million.
- As far as peak fluctuations go, Traws Pharma's Retained Earnings crashed by 3450.32% in 2024, and later tumbled by 214.93% in 2025.
- Traws Pharma's Retained Earnings (Quarter) stood at -$444.7 million in 2021, then fell by 4.26% to -$463.7 million in 2022, then decreased by 4.09% to -$482.6 million in 2023, then tumbled by 34.5% to -$649.2 million in 2024, then increased by 2.56% to -$632.5 million in 2025.
- Its Retained Earnings was -$632.5 million in Q3 2025, compared to -$628.6 million in Q2 2025 and -$627.7 million in Q1 2025.